Back to search results

A Study for Cerebral Open Flow Microperfusion in Glioma or Epilepsy Surgery

This study is testing a new way to collect information from the brain during surgery. It uses a device called cerebral open flow microperfusion (OFM) catheters, along with tubing and a pump, to collect substances from the brain tissue. This is done during a planned brain surgery for either a glioma (a type of brain tumor) or for epilepsy that requires removing part of the brain. The main goals are to see if this procedure is safe and possible to do. You might be able to join if you are 18 or older, have a good performance status (meaning you can do most daily activities), and are scheduled for brain surgery at Mayo Clinic (Rochester, MN) for a glioma or epilepsy. The study is currently unclear on its recruitment status and plans to enroll 6 participants.

Study design
This is an interventional study with a planned enrollment of 6 participants. The study does not specify a phase.
What's involved
Participants will undergo intra-operative microperfusion using the study devices during their planned brain surgery. Adverse events and sample collection will be measured for 1 year.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for adverse events and sample collection for 1 year after the procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07089758

A Study for Cerebral Open Flow Microperfusion

Not Yet Recruiting
NAAges 18+InterventionalDevice feasibility
Mayo Clinic
~6 participants
Updated 2026-03-23 on ClinicalTrials.gov
What's tested:Cerebral open flow microperfusion

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adverse events
Measured over 1 year
+1 more outcome measured

Conditions

Glioma
Glioblastoma

Explore related trials

GliomaSeizure Disorder

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Terence Burns, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Neurologic Surgery Research Team
507-538-6342
Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

ECOG performance status (PS) 0, 1 or 2.
Clinical and radiographic evidence diagnosis of glioma, or a prior diagnosis of glioma (suspected WHO grade II-IV), OR clinical evidence of epileptic foci requiring a temporal lobectomy.
Clinical indication for resection as part of routine clinical care, with plan for this to be performed at Mayo Clinic (Rochester, MN).
Able and willing to provide informed consent either signed by themselves or a legally authorized representative.

Exclusion

Vulnerable populations: pregnant women, prisoners or the mentally handicapped.
Patients who are not appropriate candidates for surgery due to current or past medical history or uncontrolled concurrent illness.
Patients whom the surgeon deems to be at increased risk of adverse effects from the study.

What this trial measures

  • Adverse events1 year

    Number of patients who develop persistent adverse events deemed related (possibly, probably, definitely) to the insertion or use of microperfusate catheters. Adverse events will be measured by CTCAE 5.0.

  • Sample collection1 year

    Number of patients for whom at least 1 specimen containing \> 10 μL microperfusate is successfully collected from 2 or more locations.